Therapies against murine Candida guilliermondii infection, relationship between in vitro antifungal pharmacodynamics and outcome

Abstract Background Candida guilliermondii has been recognized as an emerging pathogen showing a decreased susceptibility to fluconazole and considerably high echinocandin MICs. Aims Evaluate the in vitro activity of anidulafungin in comparison to amphotericin B and fluconazole against different iso...

Full description

Saved in:
Bibliographic Details
Published in:Revista iberoamericana de micologia Vol. 32; no. 1; pp. 34 - 39
Main Authors: Paredes, Katihuska, Pastor, Francisco Javier, Capilla, Javier, Sutton, Deanna A, Mayayo, Emilio, Fothergill, Annette W, Guarro, Josep
Format: Journal Article
Language:English
Published: Spain Elsevier Espana 01-01-2015
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Abstract Background Candida guilliermondii has been recognized as an emerging pathogen showing a decreased susceptibility to fluconazole and considerably high echinocandin MICs. Aims Evaluate the in vitro activity of anidulafungin in comparison to amphotericin B and fluconazole against different isolates of C. guilliermondii , and their efficacy in an immunosuppressed murine model of disseminated infection. Methods The in vitro susceptibility of four strains against amphotericin B, fluconazole and anidulafungin was performed by using a reference broth microdilution method and time-kill curves. The in vivo efficacy was evaluated by determination of fungal load reduction in kidneys of infected animals receiving deoxycholate AMB at 0,8 mg/kg i.v., liposomal amphotericin B at 10 mg/kg i.v., fluconazole at 50 mg/kg, or anidulafungin at 10 mg/kg. Results Amphotericin B and anidulafungin showed fungicidal activity, while fluconazole was fungistatic for all the strains. In the murine model, liposomal amphotericin B at 10 mg/kg/day was effective in reducing the tissue burden in kidneys of mice infected with any of the tested strains. However, amphotericin B, anidulafungin and fluconazole were only effective against those strains showing low MIC values. Conclusions Liposomal amphotericin B showed the higher activity and efficacy against the two strains of C. guilliermondii , in contrast to the poor effect of fluconazole and anidulafungin. Further studies with more isolates of C. guilliermondii representing a wider range of MICs should be carried out to assess whether there is any relationship between MIC values and anidulafungin efficacy.
AbstractList Candida guilliermondii has been recognized as an emerging pathogen showing a decreased susceptibility to fluconazole and considerably high echinocandin MICs. Evaluate the in vitro activity of anidulafungin in comparison to amphotericin B and fluconazole against different isolates of C. guilliermondii, and their efficacy in an immunosuppressed murine model of disseminated infection. The in vitro susceptibility of four strains against amphotericin B, fluconazole and anidulafungin was performed by using a reference broth microdilution method and time-kill curves. The in vivo efficacy was evaluated by determination of fungal load reduction in kidneys of infected animals receiving deoxycholate AMB at 0,8 mg/kg i.v., liposomal amphotericin B at 10 mg/kg i.v., fluconazole at 50 mg/kg, or anidulafungin at 10 mg/kg. Amphotericin B and anidulafungin showed fungicidal activity, while fluconazole was fungistatic for all the strains. In the murine model, liposomal amphotericin B at 10 mg/kg/day was effective in reducing the tissue burden in kidneys of mice infected with any of the tested strains. However, amphotericin B, anidulafungin and fluconazole were only effective against those strains showing low MIC values. Liposomal amphotericin B showed the higher activity and efficacy against the two strains of C. guilliermondii, in contrast to the poor effect of fluconazole and anidulafungin. Further studies with more isolates of C. guilliermondii representing a wider range of MICs should be carried out to assess whether there is any relationship between MIC values and anidulafungin efficacy.
Abstract Background Candida guilliermondii has been recognized as an emerging pathogen showing a decreased susceptibility to fluconazole and considerably high echinocandin MICs. Aims Evaluate the in vitro activity of anidulafungin in comparison to amphotericin B and fluconazole against different isolates of C. guilliermondii , and their efficacy in an immunosuppressed murine model of disseminated infection. Methods The in vitro susceptibility of four strains against amphotericin B, fluconazole and anidulafungin was performed by using a reference broth microdilution method and time-kill curves. The in vivo efficacy was evaluated by determination of fungal load reduction in kidneys of infected animals receiving deoxycholate AMB at 0,8 mg/kg i.v., liposomal amphotericin B at 10 mg/kg i.v., fluconazole at 50 mg/kg, or anidulafungin at 10 mg/kg. Results Amphotericin B and anidulafungin showed fungicidal activity, while fluconazole was fungistatic for all the strains. In the murine model, liposomal amphotericin B at 10 mg/kg/day was effective in reducing the tissue burden in kidneys of mice infected with any of the tested strains. However, amphotericin B, anidulafungin and fluconazole were only effective against those strains showing low MIC values. Conclusions Liposomal amphotericin B showed the higher activity and efficacy against the two strains of C. guilliermondii , in contrast to the poor effect of fluconazole and anidulafungin. Further studies with more isolates of C. guilliermondii representing a wider range of MICs should be carried out to assess whether there is any relationship between MIC values and anidulafungin efficacy.
Candida guilliermondii has been recognized as an emerging pathogen showing a decreased susceptibility to fluconazole and considerably high echinocandin MICs. Evaluate the in vitro activity of anidulafungin in comparison to amphotericin B and fluconazole against different isolates of C. guilliermondii, and their efficacy in an immunosuppressed murine model of disseminated infection. The in vitro susceptibility of four strains against amphotericin B, fluconazole and anidulafungin was performed by using a reference broth microdilution method and time-kill curves. The in vivo efficacy was evaluated by determination of fungal load reduction in kidneys of infected animals receiving deoxycholate AMB at 0,8mg/kg i.v., liposomal amphotericin B at 10mg/kg i.v., fluconazole at 50mg/kg, or anidulafungin at 10mg/kg. Amphotericin B and anidulafungin showed fungicidal activity, while fluconazole was fungistatic for all the strains. In the murine model, liposomal amphotericin B at 10mg/kg/day was effective in reducing the tissue burden in kidneys of mice infected with any of the tested strains. However, amphotericin B, anidulafungin and fluconazole were only effective against those strains showing low MIC values. Liposomal amphotericin B showed the higher activity and efficacy against the two strains of C. guilliermondii, in contrast to the poor effect of fluconazole and anidulafungin. Further studies with more isolates of C. guilliermondii representing a wider range of MICs should be carried out to assess whether there is any relationship between MIC values and anidulafungin efficacy. Candida guilliermondii es un patógeno emergente, con reducida sensibilidad al fluconazol y a las equinocandinas. Evaluar la actividad in vitro de la anidulafungina, en comparación con la de la anfotericina B y el fluconazol, frente a C. guilliermondii y su eficacia en un modelo animal de infección diseminada. La sensibilidad in vitro se valoró mediante microdilución en caldo y curvas de mortalidad. La eficacia in vivo se evaluó mediante la determinación de la carga fúngica en riñón de ratones inmunosuprimidos con infección diseminada por C. guilliermondii tratados con anfotericina B desoxicolato (0.8mg/kg i.v.), anfotericina B liposomal (10mg/kg i.v.), fluconazol (50mg/kg) o anidulafungina (10mg/kg). La anfotericina B y la anidulafungina mostraron actividad fungicida, mientras que el fluconazol fue fungistático frente a todas las cepas. En el modelo murino, la anfotericina B liposomal redujo para todas las cepas la carga fúngica en riñones, mientras que la anfotericina B desoxicolato, la anidulafungina y el fluconazol fueron efectivas solo en aquellos animales infectados con las cepas de menor valor de concentración mínima inhibitoria (CMI). La anfotericina B liposomal mostró la mayor actividad y eficacia frente a C. guilliermondii, en contraste con el limitado efecto del fluconazol y de la anidulafungina. Se necesitan estudios que incluyan cepas con un rango más amplio de CMI que permitan determinar la relación entre la actividad in vitro y la eficacia de la anidulafungina.
Author Mayayo, Emilio
Sutton, Deanna A
Pastor, Francisco Javier
Paredes, Katihuska
Guarro, Josep
Fothergill, Annette W
Capilla, Javier
Author_xml – sequence: 1
  fullname: Paredes, Katihuska
– sequence: 2
  fullname: Pastor, Francisco Javier
– sequence: 3
  fullname: Capilla, Javier
– sequence: 4
  fullname: Sutton, Deanna A
– sequence: 5
  fullname: Mayayo, Emilio
– sequence: 6
  fullname: Fothergill, Annette W
– sequence: 7
  fullname: Guarro, Josep
BackLink https://www.ncbi.nlm.nih.gov/pubmed/24594291$$D View this record in MEDLINE/PubMed
BookMark eNp9kc1u1DAQxy1U1G5LX4AD8gOQxeOk2URCSGgFLVKlHihny7HHu7MkdmQnrfbGo-NogQOHHix7Pv4znt9csjMfPDL2FsQaBNQfDutIelhLAWV2rIVoXrGVhE1ZtNA0Z2wFUIoCKlFfsMuUDkLIWgCcswtZ3bSVbGHFfj3uMeqRMHG90-TTxIc5kke-1d6S1Xw3U98TxiFkmzh5h2ai4N_ziL1eXmlPI-9wekb0Oc6faIqBaz-Rm_1O93zc6zhoE-zR64FMbuUtD_NkwoBv2Gun-4TXf-4r9uPrl8ftXXH_cPtt-_m-MFUDU-EQa2c6fVOVdVVCKRvTuda5jYCuqoWVoMHaDVrbOZPnhka2dYkb18jaWKzKKyZPdU0MKUV0aow06HhUINSCUx3UglMtOBdfxplF706ice4GtP8kf_nlhI-nBMxff8qUVDKE3qClmDEpG-jl-p_-k5uePBnd_8QjpkOYo89QFKgklVDfl4Uu-8xHCJB1-Rvq_aFB
CitedBy_id crossref_primary_10_1016_j_diagmicrobio_2016_05_014
crossref_primary_10_1111_myc_12468
crossref_primary_10_1128_AAC_03051_14
Cites_doi 10.1128/JCM.00865-06
10.1007/s15010-002-2131-0
10.1128/AAC.00524-06
10.1016/j.diagmicrobio.2004.07.011
10.1128/CMR.17.2.268-280.2004
10.1128/AAC.48.11.4453-4456.2004
10.1093/jac/dkr143
10.1128/AAC.00500-11
10.1128/JCM.00942-09
10.1128/AAC.50.2.469-473.2006
10.7326/0003-4819-102-1-67
10.1007/s10096-003-1013-4
10.1128/JCM.00937-12
10.1128/JCM.02117-09
10.1111/1469-0691.12041
10.1128/AAC.42.10.2467
10.1007/s101560170033
10.1016/j.drup.2011.01.004
10.1128/JCM.05047-11
10.1128/AAC.50.2.674-684.2006
10.1128/AAC.00111-06
10.1111/j.1439-0507.2010.01960.x
10.1128/AAC.43.9.2116
ContentType Journal Article
Copyright Revista Iberoamericana de Micología
2013 Revista Iberoamericana de Micología
Copyright © 2013 Revista Iberoamericana de Micología. Published by Elsevier Espana. All rights reserved.
Copyright_xml – notice: Revista Iberoamericana de Micología
– notice: 2013 Revista Iberoamericana de Micología
– notice: Copyright © 2013 Revista Iberoamericana de Micología. Published by Elsevier Espana. All rights reserved.
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
DOI 10.1016/j.riam.2013.10.008
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
DatabaseTitleList MEDLINE


Database_xml – sequence: 1
  dbid: ECM
  name: MEDLINE
  url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
DocumentTitleAlternate Terapia antifúngica frente a la infección por Candida guilliermondii en ratones, correlación entre los parámetros farmacodinámicos in vitro y la eficacia in vivo
EISSN 2173-9188
EndPage 39
ExternalDocumentID 10_1016_j_riam_2013_10_008
24594291
S1130140614000126
1_s2_0_S1130140614000126
Genre Journal Article
GroupedDBID ---
0R~
0SF
123
2WC
36B
4.4
457
65R
AACTN
AAEDT
AAEDW
AAHBH
AALRI
AAQFI
AAXKI
AAXUO
ABJNI
ACGFS
ACRLP
ADBBV
ADCUG
ADVLN
AEBSH
AENEX
AEVXI
AFJKZ
AFKWA
AFTJW
AFXIZ
AIEXJ
AIKHN
AITUG
AKRWK
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
AXJTR
BAWUL
BNPGV
CJTIS
DIK
DU5
EBD
EBS
EFJIC
EJD
EMB
EML
EMOBN
FDB
FIRID
FRP
FYGXN
GX1
HZ~
MM.
O9-
OK1
RIG
SES
SSH
SSI
SV3
T5K
W2D
Z7D
EFLBG
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
ID FETCH-LOGICAL-c481t-fee6fcba5436431328cbf9ff701b460d21a1dd7eddbfc113182963e7f826cde43
ISSN 1130-1406
IngestDate Thu Sep 26 16:47:26 EDT 2024
Fri Nov 25 08:30:23 EST 2022
Fri Feb 23 02:29:07 EST 2024
Tue Oct 15 22:56:10 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Candida guilliermondii
Animal model
Modelo animal
Infección fúngica
Fungal infection
Language English
License Copyright © 2013 Revista Iberoamericana de Micología. Published by Elsevier Espana. All rights reserved.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c481t-fee6fcba5436431328cbf9ff701b460d21a1dd7eddbfc113182963e7f826cde43
PMID 24594291
PageCount 6
ParticipantIDs crossref_primary_10_1016_j_riam_2013_10_008
pubmed_primary_24594291
elsevier_sciencedirect_doi_10_1016_j_riam_2013_10_008
elsevier_clinicalkeyesjournals_1_s2_0_S1130140614000126
PublicationCentury 2000
PublicationDate 2015-01-01
PublicationDateYYYYMMDD 2015-01-01
PublicationDate_xml – month: 01
  year: 2015
  text: 2015-01-01
  day: 01
PublicationDecade 2010
PublicationPlace Spain
PublicationPlace_xml – name: Spain
PublicationTitle Revista iberoamericana de micologia
PublicationTitleAlternate Rev Iberoam Micol
PublicationYear 2015
Publisher Elsevier Espana
Publisher_xml – name: Elsevier Espana
References Clinical Laboratory Standards Institute (bib0030) 2008
Ullmann, Akova, Herbrecht, Viscoli, Arendrup, Arikan-Akdagli (bib0115) 2012; 18
Graybill, Bocanegra, Najvar, Loebenberg, Luther (bib0050) 1998; 42
Guarro (bib0055) 2011; 66
Pfaller, Diekema, Gibbs, Newell, Ellis, Tullio (bib0090) 2010; 48
Pfaller, Diekema, Andes, Arendrup, Brown, Lockhart (bib0085) 2011; 14
Pfaller, Diekema (bib0080) 2012; 50
Di Bonaventura, Spedicato, Picciani, D’Antonio, Piccolomini (bib0035) 2004; 48
Andes, van Ogtrop (bib0010) 1999; 43
Cantón, Pemán, Sastre, Romero, Espinel-Ingroff (bib0025) 2006; 50
Salas, Pastor, Calvo, Mayayo, Quindós, Carillo (bib0105) 2011; 55
Ortoneda, Capilla, Pastor, Guarro (bib0070) 2004; 50
Barchiesi, Spreghini, Tomassetti, Della Vittoria, Arzeni, Manso (bib0020) 2006; 50
Diekema, Messer, Boyken, Hollis, Kroeger, Tendolkar (bib0040) 2009; 47
Savini, Catavitello, Onofrillo, Masciarelli, Astolfi, Balbinot (bib0110) 2011; 54
Pfaller, Castanheira, Diekema, Messer, Jones (bib0075) 2011; 49
Pfaller, Sheehan, Rex (bib0100) 2004; 17
Pfaller, Diekema, Mendez, Kibbler, Erzsebet, Chang (bib0095) 2006; 44
Arendrup, Horn, Frimodt-Møller (bib0015) 2002; 30
Masala, Luzzati, Maccacaro, Antozzi, Concia, Fontana (bib0065) 2003; 22
Kovacicova, Hanzen, Pisarcikova, Sejnova, Horn, Babela (bib0060) 2001; 7
Vazquez, Lundstrom, Dembry, Chandrasekar, Boikov, Parri (bib0120) 1995; 16
Andes, Safdar, Marchillo, Conklin (bib0005) 2006; 50
Dick, Rosengard, Merz, Stuart, Hutchins, Saral (bib0045) 1985; 102
Wiederhold, Tam, Chi, Prince, Kontoyiannis, Lewis (bib0125) 2006; 50
Salas (10.1016/j.riam.2013.10.008_bib0105) 2011; 55
Clinical Laboratory Standards Institute (10.1016/j.riam.2013.10.008_bib0030) 2008
Ortoneda (10.1016/j.riam.2013.10.008_bib0070) 2004; 50
Barchiesi (10.1016/j.riam.2013.10.008_bib0020) 2006; 50
Ullmann (10.1016/j.riam.2013.10.008_bib0115) 2012; 18
Pfaller (10.1016/j.riam.2013.10.008_bib0085) 2011; 14
Pfaller (10.1016/j.riam.2013.10.008_bib0090) 2010; 48
Guarro (10.1016/j.riam.2013.10.008_bib0055) 2011; 66
Wiederhold (10.1016/j.riam.2013.10.008_bib0125) 2006; 50
Dick (10.1016/j.riam.2013.10.008_bib0045) 1985; 102
Pfaller (10.1016/j.riam.2013.10.008_bib0075) 2011; 49
Graybill (10.1016/j.riam.2013.10.008_bib0050) 1998; 42
Arendrup (10.1016/j.riam.2013.10.008_bib0015) 2002; 30
Pfaller (10.1016/j.riam.2013.10.008_bib0100) 2004; 17
Andes (10.1016/j.riam.2013.10.008_bib0005) 2006; 50
Cantón (10.1016/j.riam.2013.10.008_bib0025) 2006; 50
Diekema (10.1016/j.riam.2013.10.008_bib0040) 2009; 47
Savini (10.1016/j.riam.2013.10.008_bib0110) 2011; 54
Pfaller (10.1016/j.riam.2013.10.008_bib0080) 2012; 50
Pfaller (10.1016/j.riam.2013.10.008_bib0095) 2006; 44
Vazquez (10.1016/j.riam.2013.10.008_bib0120) 1995; 16
Andes (10.1016/j.riam.2013.10.008_bib0010) 1999; 43
Kovacicova (10.1016/j.riam.2013.10.008_bib0060) 2001; 7
Di Bonaventura (10.1016/j.riam.2013.10.008_bib0035) 2004; 48
Masala (10.1016/j.riam.2013.10.008_bib0065) 2003; 22
References_xml – year: 2008
  ident: bib0030
  article-title: Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard. Document M27-A3
  contributor:
    fullname: Clinical Laboratory Standards Institute
– volume: 43
  start-page: 2116
  year: 1999
  end-page: 2120
  ident: bib0010
  article-title: Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model
  publication-title: Antimicrob Agents Chemother
  contributor:
    fullname: van Ogtrop
– volume: 18
  start-page: 53
  year: 2012
  end-page: 67
  ident: bib0115
  article-title: ESCMID guideline for the diagnosis and management of
  publication-title: Clin Microbiol Infect
  contributor:
    fullname: Arikan-Akdagli
– volume: 16
  start-page: 849
  year: 1995
  end-page: 853
  ident: bib0120
  article-title: Invasive
  publication-title: Bone Marrow Transplant
  contributor:
    fullname: Parri
– volume: 102
  start-page: 67
  year: 1985
  end-page: 68
  ident: bib0045
  article-title: Fatal disseminated candidiasis due to amphotericin B-resistant
  publication-title: Ann Intern Med
  contributor:
    fullname: Saral
– volume: 49
  start-page: 3800
  year: 2011
  end-page: 3804
  ident: bib0075
  article-title: Triazole and echinocandin MIC distributions with epidemiological cutoff values for differentiation of wild-type strains from non-wild-type strains of six uncommon species of
  publication-title: J Clin Microbiol
  contributor:
    fullname: Jones
– volume: 48
  start-page: 1366
  year: 2010
  end-page: 1377
  ident: bib0090
  article-title: Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of
  publication-title: J Clin Microbiol
  contributor:
    fullname: Tullio
– volume: 50
  start-page: 247
  year: 2004
  end-page: 251
  ident: bib0070
  article-title: Interaction of granulocyte colony-stimulating factor and high doses of liposomal amphotericin B in the treatment of systemic murine scedosporiosis
  publication-title: Diagn Microbiol Infect Dis
  contributor:
    fullname: Guarro
– volume: 22
  start-page: 686
  year: 2003
  end-page: 688
  ident: bib0065
  article-title: Nosocomial cluster of
  publication-title: Eur J Clin Microbiol Infect Dis
  contributor:
    fullname: Fontana
– volume: 50
  start-page: 2846
  year: 2012
  end-page: 2856
  ident: bib0080
  article-title: Progress in antifungal susceptibility testing of
  publication-title: J Clin Microbiol
  contributor:
    fullname: Diekema
– volume: 14
  start-page: 164
  year: 2011
  end-page: 176
  ident: bib0085
  article-title: Clinical breakpoints for the echinocandins and
  publication-title: Drug Resist Updat
  contributor:
    fullname: Lockhart
– volume: 50
  start-page: 2719
  year: 2006
  end-page: 2727
  ident: bib0020
  article-title: Effects of caspofungin against
  publication-title: Antimicrob Agents Chemother
  contributor:
    fullname: Manso
– volume: 50
  start-page: 2829
  year: 2006
  end-page: 2832
  ident: bib0025
  article-title: Killing kinetics of caspofungin, micafungin, and amphotericin B against
  publication-title: Antimicrob Agents Chemother
  contributor:
    fullname: Espinel-Ingroff
– volume: 55
  start-page: 4985
  year: 2011
  end-page: 4989
  ident: bib0105
  article-title: Anidulafungin in treatment of experimental invasive infection by
  publication-title: Antimicrob Agents Chemoter
  contributor:
    fullname: Carillo
– volume: 48
  start-page: 4453
  year: 2004
  end-page: 4456
  ident: bib0035
  article-title: In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent
  publication-title: Antimicrob Agents Chemother
  contributor:
    fullname: Piccolomini
– volume: 44
  start-page: 3551
  year: 2006
  end-page: 3556
  ident: bib0095
  article-title: , an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program
  publication-title: J Clin Microbiol
  contributor:
    fullname: Chang
– volume: 50
  start-page: 674
  year: 2006
  end-page: 684
  ident: bib0005
  article-title: Pharmacokinetic–pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models
  publication-title: Antimicrob Agents Chemother
  contributor:
    fullname: Conklin
– volume: 66
  start-page: 1447
  year: 2011
  end-page: 1466
  ident: bib0055
  article-title: Lessons from animal studies for the treatment of invasive human infections due to uncommon fungi
  publication-title: J Antimicrob Chemother
  contributor:
    fullname: Guarro
– volume: 7
  start-page: 45
  year: 2001
  end-page: 48
  ident: bib0060
  article-title: Nosocomial fungemia due to amphotericin B-resistant
  publication-title: J Infect Chemother
  contributor:
    fullname: Babela
– volume: 50
  start-page: 469
  year: 2006
  end-page: 473
  ident: bib0125
  article-title: Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis
  publication-title: Antimicrob Agents Chemother
  contributor:
    fullname: Lewis
– volume: 47
  start-page: 3170
  year: 2009
  end-page: 3177
  ident: bib0040
  article-title: In vitro activity of seven systemically active antifungal agents against a large global collection of rare
  publication-title: J Clin Microbiol
  contributor:
    fullname: Tendolkar
– volume: 17
  start-page: 268
  year: 2004
  end-page: 280
  ident: bib0100
  article-title: Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization
  publication-title: Clin Microb Rev
  contributor:
    fullname: Rex
– volume: 42
  start-page: 2467
  year: 1998
  end-page: 2473
  ident: bib0050
  article-title: Granulocyte colony-stimulating factor and azole antifungal therapy in murine aspergillosis: role of immune suppression
  publication-title: Antimicrob Agents Chemother
  contributor:
    fullname: Luther
– volume: 30
  start-page: 286
  year: 2002
  end-page: 291
  ident: bib0015
  article-title: In vivo pathogenicity of eight medically relevant
  publication-title: Infection
  contributor:
    fullname: Frimodt-Møller
– volume: 54
  start-page: 434
  year: 2011
  end-page: 441
  ident: bib0110
  article-title: What do we know about
  publication-title: Mycoses
  contributor:
    fullname: Balbinot
– volume: 44
  start-page: 3551
  year: 2006
  ident: 10.1016/j.riam.2013.10.008_bib0095
  article-title: Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program
  publication-title: J Clin Microbiol
  doi: 10.1128/JCM.00865-06
  contributor:
    fullname: Pfaller
– volume: 30
  start-page: 286
  year: 2002
  ident: 10.1016/j.riam.2013.10.008_bib0015
  article-title: In vivo pathogenicity of eight medically relevant Candida species in an animal model
  publication-title: Infection
  doi: 10.1007/s15010-002-2131-0
  contributor:
    fullname: Arendrup
– volume: 50
  start-page: 2829
  year: 2006
  ident: 10.1016/j.riam.2013.10.008_bib0025
  article-title: Killing kinetics of caspofungin, micafungin, and amphotericin B against Candida guilliermondii
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.00524-06
  contributor:
    fullname: Cantón
– volume: 50
  start-page: 247
  year: 2004
  ident: 10.1016/j.riam.2013.10.008_bib0070
  article-title: Interaction of granulocyte colony-stimulating factor and high doses of liposomal amphotericin B in the treatment of systemic murine scedosporiosis
  publication-title: Diagn Microbiol Infect Dis
  doi: 10.1016/j.diagmicrobio.2004.07.011
  contributor:
    fullname: Ortoneda
– volume: 17
  start-page: 268
  year: 2004
  ident: 10.1016/j.riam.2013.10.008_bib0100
  article-title: Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization
  publication-title: Clin Microb Rev
  doi: 10.1128/CMR.17.2.268-280.2004
  contributor:
    fullname: Pfaller
– volume: 48
  start-page: 4453
  year: 2004
  ident: 10.1016/j.riam.2013.10.008_bib0035
  article-title: In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.48.11.4453-4456.2004
  contributor:
    fullname: Di Bonaventura
– volume: 66
  start-page: 1447
  year: 2011
  ident: 10.1016/j.riam.2013.10.008_bib0055
  article-title: Lessons from animal studies for the treatment of invasive human infections due to uncommon fungi
  publication-title: J Antimicrob Chemother
  doi: 10.1093/jac/dkr143
  contributor:
    fullname: Guarro
– volume: 55
  start-page: 4985
  year: 2011
  ident: 10.1016/j.riam.2013.10.008_bib0105
  article-title: Anidulafungin in treatment of experimental invasive infection by Candida parapsilosis: in vitro activity, (1→3)-beta-d-glucan and mannan serum levels, histopathological findings, and in vivo efficacy
  publication-title: Antimicrob Agents Chemoter
  doi: 10.1128/AAC.00500-11
  contributor:
    fullname: Salas
– volume: 47
  start-page: 3170
  year: 2009
  ident: 10.1016/j.riam.2013.10.008_bib0040
  article-title: In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods
  publication-title: J Clin Microbiol
  doi: 10.1128/JCM.00942-09
  contributor:
    fullname: Diekema
– year: 2008
  ident: 10.1016/j.riam.2013.10.008_bib0030
  contributor:
    fullname: Clinical Laboratory Standards Institute
– volume: 50
  start-page: 469
  year: 2006
  ident: 10.1016/j.riam.2013.10.008_bib0125
  article-title: Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.50.2.469-473.2006
  contributor:
    fullname: Wiederhold
– volume: 102
  start-page: 67
  year: 1985
  ident: 10.1016/j.riam.2013.10.008_bib0045
  article-title: Fatal disseminated candidiasis due to amphotericin B-resistant Candida guilliermondii
  publication-title: Ann Intern Med
  doi: 10.7326/0003-4819-102-1-67
  contributor:
    fullname: Dick
– volume: 22
  start-page: 686
  year: 2003
  ident: 10.1016/j.riam.2013.10.008_bib0065
  article-title: Nosocomial cluster of Candida guilliermondii fungemia in surgical patients
  publication-title: Eur J Clin Microbiol Infect Dis
  doi: 10.1007/s10096-003-1013-4
  contributor:
    fullname: Masala
– volume: 50
  start-page: 2846
  year: 2012
  ident: 10.1016/j.riam.2013.10.008_bib0080
  article-title: Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012
  publication-title: J Clin Microbiol
  doi: 10.1128/JCM.00937-12
  contributor:
    fullname: Pfaller
– volume: 48
  start-page: 1366
  year: 2010
  ident: 10.1016/j.riam.2013.10.008_bib0090
  article-title: Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion
  publication-title: J Clin Microbiol
  doi: 10.1128/JCM.02117-09
  contributor:
    fullname: Pfaller
– volume: 18
  start-page: 53
  issue: Suppl. 7
  year: 2012
  ident: 10.1016/j.riam.2013.10.008_bib0115
  article-title: ESCMID guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT)
  publication-title: Clin Microbiol Infect
  doi: 10.1111/1469-0691.12041
  contributor:
    fullname: Ullmann
– volume: 42
  start-page: 2467
  year: 1998
  ident: 10.1016/j.riam.2013.10.008_bib0050
  article-title: Granulocyte colony-stimulating factor and azole antifungal therapy in murine aspergillosis: role of immune suppression
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.42.10.2467
  contributor:
    fullname: Graybill
– volume: 7
  start-page: 45
  year: 2001
  ident: 10.1016/j.riam.2013.10.008_bib0060
  article-title: Nosocomial fungemia due to amphotericin B-resistant Candida spp. in three pediatric patients after previous neurosurgery for brain tumors
  publication-title: J Infect Chemother
  doi: 10.1007/s101560170033
  contributor:
    fullname: Kovacicova
– volume: 14
  start-page: 164
  year: 2011
  ident: 10.1016/j.riam.2013.10.008_bib0085
  article-title: Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria
  publication-title: Drug Resist Updat
  doi: 10.1016/j.drup.2011.01.004
  contributor:
    fullname: Pfaller
– volume: 49
  start-page: 3800
  year: 2011
  ident: 10.1016/j.riam.2013.10.008_bib0075
  article-title: Triazole and echinocandin MIC distributions with epidemiological cutoff values for differentiation of wild-type strains from non-wild-type strains of six uncommon species of Candida
  publication-title: J Clin Microbiol
  doi: 10.1128/JCM.05047-11
  contributor:
    fullname: Pfaller
– volume: 50
  start-page: 674
  year: 2006
  ident: 10.1016/j.riam.2013.10.008_bib0005
  article-title: Pharmacokinetic–pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.50.2.674-684.2006
  contributor:
    fullname: Andes
– volume: 50
  start-page: 2719
  year: 2006
  ident: 10.1016/j.riam.2013.10.008_bib0020
  article-title: Effects of caspofungin against Candida guilliermondii and Candida parapsilosis
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.00111-06
  contributor:
    fullname: Barchiesi
– volume: 54
  start-page: 434
  year: 2011
  ident: 10.1016/j.riam.2013.10.008_bib0110
  article-title: What do we know about Candida guilliermondii? A voyage throughout past and current literature about this emerging yeast
  publication-title: Mycoses
  doi: 10.1111/j.1439-0507.2010.01960.x
  contributor:
    fullname: Savini
– volume: 43
  start-page: 2116
  year: 1999
  ident: 10.1016/j.riam.2013.10.008_bib0010
  article-title: Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.43.9.2116
  contributor:
    fullname: Andes
– volume: 16
  start-page: 849
  year: 1995
  ident: 10.1016/j.riam.2013.10.008_bib0120
  article-title: Invasive Candida guilliermondii infection: in vitro susceptibility studies and molecular analysis
  publication-title: Bone Marrow Transplant
  contributor:
    fullname: Vazquez
SSID ssj0026011
ssib019627658
Score 2.067951
Snippet Abstract Background Candida guilliermondii has been recognized as an emerging pathogen showing a decreased susceptibility to fluconazole and considerably high...
Candida guilliermondii has been recognized as an emerging pathogen showing a decreased susceptibility to fluconazole and considerably high echinocandin MICs....
SourceID crossref
pubmed
elsevier
SourceType Aggregation Database
Index Database
Publisher
StartPage 34
SubjectTerms Amphotericin B - pharmacology
Animal model
Animals
Antifungal Agents - pharmacology
Antifungal Agents - therapeutic use
Candida - drug effects
Candida - isolation & purification
Candida guilliermondii
Candidiasis, Invasive - drug therapy
Candidiasis, Invasive - etiology
Candidiasis, Invasive - microbiology
Communicable Diseases, Emerging - microbiology
Drug Evaluation, Preclinical
Echinocandins - pharmacology
Fluconazole - pharmacology
Fungal infection
Infección fúngica
Infectious Disease
Kidney - microbiology
Male
Mice
Microbial Sensitivity Tests
Modelo animal
Neutropenia - complications
Random Allocation
Species Specificity
Title Therapies against murine Candida guilliermondii infection, relationship between in vitro antifungal pharmacodynamics and outcome
URI https://www.clinicalkey.es/playcontent/1-s2.0-S1130140614000126
https://dx.doi.org/10.1016/j.riam.2013.10.008
https://www.ncbi.nlm.nih.gov/pubmed/24594291
Volume 32
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lj9MwELa6y4ULAvEqL_nALaSKEzdJj6s2aGEFQuoicbMcP5YuIqmahDM_nXHsOKEr8ZI41GptNbY8X-blmTFCL_OV1vA-0zADKyekhOpwJaBJcx5FpYwi3buyz7fZ-0_5pqDFbDbcJjD2_VdKQx_Q2mTO_gW1_UOhA74DzaEFqkP7p3Q_8D3YvwG_Aqu_aYOvxqGugrVJYJE8uOqMiwUYcg2_dz4aq-c-hyE0bhrCtauCb7v2UAfcBBYBczDJW67itbQX2ttCz3XXiqPiB-boAfTPoI9L4e50iAcmbHbX18vuD-o3XjZ8MPHwlnNdwEo-d82XyVjTWueCuw1E1MFbbuT6eJCyN5co2ejf6cC2a12awEbxChZwtpi6O8jyyN3h83AKYLj2fnHHuUEYh2AtplPWPrpOPYQtn3YOVCvxbTWlG7LEujWuFwANU7KAJIs-DDAfJaePZ9ya2c3k8DEKZHqCbsXA-UyM6ebNhfcAgPXbewCGtbosLhtweDzPbzSliRp0eRfdcfYLPrPAu4dmqrqPvnvQYQc6bEGHHejwz6DDHnSv8BRy2EEOxnEPOTxCDh9DDsYkdpB7gD6-Li7X56G72iMUNCdtqJVKtSj5kiagEpMkzkWpzfFBREqaRjImnEiZKSlLLWC7wAoGSaEyDdawkIomD9FpVVfqMcIi0rSUutRpLqiQSVkqKjMiMxDzuUyiOQqGbWR7W8GFDaGN18xsOjObbvpg0-coG3aaDbnJIE1V417xhhHWxCxiN0g-R0v_T6e9Wq2UAaB-OeMjS1C_upguV6Amkif_-MSn6Pb45jxDp-2hU8_RSSO7Fz0coS3W734AlPLOpQ
link.rule.ids 315,782,786,27935,27936
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Therapies+against+murine+Candida+guilliermondii+infection%2C+relationship+between+in+vitro+antifungal+pharmacodynamics+and+outcome&rft.jtitle=Revista+iberoamericana+de+micolog%C3%ADa&rft.au=Paredes%2C+Katihuska&rft.au=Pastor%2C+Francisco+Javier&rft.au=Capilla%2C+Javier&rft.au=Sutton%2C+Deanna+A.&rft.date=2015-01-01&rft.pub=Elsevier+Espana&rft.issn=1130-1406&rft.volume=32&rft.issue=1&rft.spage=34&rft.epage=39&rft_id=info:doi/10.1016%2Fj.riam.2013.10.008&rft.externalDocID=S1130140614000126
thumbnail_m http://sdu.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F11301406%2FS1130140614X00057%2Fcov150h.gif